Elios Therapeutics - Investors & Media
  • Home
  • Clinical Trial
    • Autologous TLPO Vaccine Basket
  • Company
  • Our Story
  • Science
    • Pipeline
    • Publications & Presentations
  • Get Started

Elios Therapeutics Announces the Appointment of Mark H.N. Corrigan, M.D. as Chairman of the Board of Directors

by info@wpmakeovers.com | Feb 10, 2022 | Investors & Media

Elios Strengthens Board of Directors with Appointment of Key Financial Executive Michael Caprio

by info@wpmakeovers.com | Sep 29, 2021 | Investors & Media

Recent Posts

  • Elios Therapeutics Announces the Appointment of Mark H.N. Corrigan, M.D. as Chairman of the Board of Directors
  • Randomized Trial of Tumor Lysate Particle Only Vaccine vs. Tumor Lysate Particle-loaded, Dendritic Cell Vaccine to Prevent Recurrence of Resected Stage III/IV Melanoma: 36-MonthAnalysis – Society for Immunotherapy of Cancer
  • Tumor Lysate Particle Only Vaccine (TLPO) vs. Tumor Lysate Particle-loaded, Dendritic Cell (TLPLDC) Vaccine to Prevent Recurrence in Resected Stage III/IV Melanoma Patients: Results of a Phase I/IIaTrial
  • Elios Strengthens Board of Directors with Appointment of Key Financial Executive Michael Caprio

Recent Comments

No comments to show.
Elios Therapeutics - Investors & Media

Location

111 Smith Hines Road, Suite E
Greenville, SC 29607

Quick Links

  • Clinical Trial
  • Company
  • Our Story
  • Science
Copyright © 2024 Elios Therapeutics | Designed by WPMakeovers.com